Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS 

Sanofi’s $3.4 billion takeout of its partner Principia gives it full control of an MS program to which it already held rights, allowing the French pharma to expand the Btk inhibitor’s reach into additional CNS indications.

Sanofi (Euronext:SAN; NASDAQ:SNY) also gains two more clinical programs targeting Btk and a small molecule platform that could yield further candidates and effectively buys out its own milestone and royalty obligations to Principia Biopharma Inc. (NASDAQ:PRNB) for SAR442168. That oral, brain-penetrant Btk inhibitor is in Phase III testing for multiple sclerosis. ...